Page 228 - Genentech News Today

The Elecsys® Alzheimer’s disease (AD) CSF assays will be available on the cobas fully automated immunoassay analyzers, enabling patients to get broad...

ZÜRICH, Switzerland, Dec. 08, 2022., a biotechnology company pioneering a new and differentiated class of highly tumor-selective immuno-oncology therapeutics based on its proprietary antibody-based MHC-targeting

Mark Filip, a former federal judge, will lead the investigation into Stanford president Marc Tessier-Lavigne.

Investegate announcements from BioNTech SE, Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years

Bivalent vaccine authorized as third 3-µg dose in the three-dose primary seriesConsistent COVID-19 hospitalization rates in this age group coupled with an overall surge in respiratory illnesses among children

/PRNewswire/ -- Vaniam Group today announced the hiring of Matthew M. Burke, DNP, MBA, RN, APRN-BC, to lead the companys Clinical Strategy & Solutions (CSS)...

Bivalent vaccine authorized as third 3-µg dose in the three-dose primary series Consistent COVID-19 hospitalization rates in this age group coupled with an overall surge in respiratory illnesses

MINV invests in innovation in Asia ex-Japan, capitalizing on the new economy and rising disposable income in the region.

/PRNewswire/ -- Vaniam Group today announced the hiring of Matthew M. Burke, DNP, MBA, RN, APRN-BC, to lead the companys Clinical Strategy & Solutions (CSS)...

Unlike most other Alzheimer’s prevention trials, this one will enroll people up to 25 years before the expected onset of dementia. Some participants could be as young as 18.